Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 12, Pages 5924-5930Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00656-13
Keywords
-
Categories
Funding
- Cubist Pharmaceuticals, Inc., Lexington, MA
- Achaogen
- Astellas
- AstraZeneca
- Basilea Pharmaceutica
- Bayer HealthCare
- Bristol-Meyers Squibb
- Cempra Pharmaceuticals
- Cerexa
- Cubist Pharmaceuticals
- Durata Pharmaceuticals
- Fedora Pharmaceuticals
- Forest Research Institute
- Furiex Pharmaceuticals
- GlaxoSmithKline
- Meiji Seika Pharma
- Nabriva Therapeutics
- Nimbus
- Pfizer
- PolyMedix
- Rib-X
- Roche Bioscience
- Rock Therapeutics
- Tetraphase Pharmaceuticals
- Medicines Company
- American Proficiency Institute (API)
- Anacor
- Bayer
- Cempra
- Contrafect
- Cubist
- Daiichi
- Dipexium
- Enanta
- Furiex
- Johnson & Johnson (Ortho McNeil)
- LegoChem Biosciences Inc.
- Meiji Seika Kaisha
- Merck
- Nabriva
- Novartis
- Pfizer (Wyeth)
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Medicines Co.
- Theravance
- ThermoFisher
Ask authors/readers for more resources
We recently investigated the pharmacokinetics-pharmacodynamics (PK-PD) of tazobactam in combination with ceftolozane against an isogenic CTX-M-15-producing Escherichia coli triplet set, genetically engineered to transcribe different levels of bla(CTX-M-15). The percentage of the dosing interval that tazobactam concentrations remained above a threshold (% Time>threshold) was identified as the PK-PD exposure measure that was most closely associated with efficacy. Moreover, the tazobactam concentration was dependent upon the enzyme transcription level. Given that the aforementioned strains were genetically engineered to transcribe a single beta-lactamase enzyme and that clinical isolates typically produce multiple beta-lactamase enzymes with various transcription levels, it is likely that the tazobactam threshold concentration is isolate/enzyme dependent. Our first objective was to characterize the relationship between the tazobactam % Time>threshold in combination with ceftolozane and efficacy using clinical isolates in an in vitro PK-PD infection model. Our second objective was to identify a translational relationship that would allow for the comodeling across clinical isolates. The initial challenge panel included four well-characterized beta-lactamase-producing E. coli strains with variable enzyme expression and other resistance determinants. As evidenced by r(2) values of ranging from 0.90 to 0.99 for each clinical isolate, the observed data were well described by fitted functions describing the relationship between the tazobactam % Time>threshold and change in log(10) CFU from baseline; however, the data from the four isolates did not comodel well. The threshold concentration identified for each isolate ranged from 0.5 to 4 mg/liter. We identified an enabling translational relationship for the tazobactam threshold that allowed co-modeling of all four clinical isolates, which was the product of the individual isolate's ceftolozane-tazobactam MIC value and 0.5. As evidenced by an r(2) value of 0.90, the transformed data were well described by a fitted function describing the relationship between tazobactam % Time>threshold and change in log(10) CFU from baseline. Due to these findings, the challenge panel was expanded to include three well-characterized beta-lactamase-producing Klebsiella pneumoniae strains with variable enzyme expression and other resistance determinants. The translational relationship for the tazobactam threshold that allowed for the comodeling of the four E. coli isolates performed well for the expanded data set (seven isolates in total; four E. coli and three K. pneumoniae), as evidenced by an r(2) value of 0.84. This simple translational relationship is especially useful as it is directly linked to in vitro susceptibility test results, which are used to guide the clinician's choice of drug and dosing regimen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available